Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.90 2.28 +6.23%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 2 3
ROE
(7.20%) (15.40%) (5.72%) (5.47%)
ROA
(6.64%) (14.69%) (5.38%) (5.15%)
ROIC
(171.36%) (170.97%) (32.17%) (34.51%)
Return on Tangible Assets
(8.49%) (17.90%) (6.12%) (5.96%)
Average Days of Receivables
0.00 0.00 34,035.81 37,392.97
Free Cash Flow per Share
(1.15) (1.10) (1.08) (1.14)
Free Cash Flow
(784.38) (766.85) (758.56) (821.06)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026